Treatment of age-related macular degeneration: Beyond VEGF

Japanese Journal of Ophthalmology

Volumn 54, Issue 6, 2010, Pages 523-528

  Miller, Joan W ^a,b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

age related macular degeneration; anti VEGF therapies; apoptosis; Bruch membrane; genetic associations

Indexed keywords

BEVACIZUMAB; COLLAGEN; COLLAGEN TYPE 18; COMPLEMENT FACTOR H; ELASTIN; ENDOSTATIN; LYSYL OXIDASE LIKE PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PEGAPTANIB; PROTEIN LYSINE 6 OXIDASE; RANIBIZUMAB; STEROID; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN;

BRUCH MEMBRANE; DRUG APPROVAL; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; HUMAN; NONHUMAN; PATHOGENESIS; PHOTODYNAMIC THERAPY; PHOTORECEPTOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; TREATMENT PLANNING;

DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78751640835     PISSN: 00215155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10384-010-0863-4     Document Type: Review

References (54)

1. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-1436.
2. J. Miller U. Schmidt-Erfurth M. Sickenberg, et al. 1999 Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of a single treatment in a phase 1 and 2 study Arch Ophthalmol 117 1161 1173 1:CAS:528:DyaK1MXmsVantr4%3D 10496388 (Pubitemid 29428825)
3. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-1345.
4. M. Gillies J. Simpson W. Luo, et al. 2003 A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results Arch Ophthalmol 121 667 673 1:CAS:528:DC%2BD3sXkt1Siu7c%3D 10.1001/archopht.121.5.667 12742844 (Pubitemid 36554469)
5. M.C. Gilles J. Larsson 2007 The effect of intravitreal triamcinolone on foveal edema in exudative macular degeneration Am J Ophthalmol 144 134 136 10.1016/j.ajo.2007.03.019 (Pubitemid 46963186)
6. R.F. Spaide J. Sorenson L. Maranan 2003 Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization Ophthalmology 110 1517 1525 10.1016/S0161-6420(03)00544-X 12917166 (Pubitemid 36962483)
7. E.S. Gragoudas A. Adamis E.J. Cunningham M. Feinsod D. Guyer 2004 Pegaptanib for neovascular age-related macular degeneration N Eng J Med 351 2805 2816 1:CAS:528:DC%2BD2MXhslyntw%3D%3D 10.1056/NEJMoa042760 (Pubitemid 40051904)
8. S. Ishida T. Usui K. Yamashiro, et al. 2003 VEGF-164-mediated inflammation is required for pathological, but not physiological, ischemiainduced retinal neovascularization J Exp Med 198 483 489 1:CAS:528:DC%2BD3sXmt1Ggsrg%3D 10.1084/jem.20022027 12900522 (Pubitemid 36976059)
9. E.W.M. Ng A.P. Adamis 2006 Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases Ann N Y Acad Sci 1082 151 171 1:CAS:528: DC%2BD2sXmvFOnsQ%3D%3D 10.1196/annals.1348.062 17145936 (Pubitemid 44955460)
10. E.W.M. Ng D.T. Shima P. Calias E.T. Cunningham Jr D.R. Guyer A.P. Adamis 2006 Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease Nat Rev Drug Discov 5 123 132 1:CAS:528:DC%2BD28Xhslaqur8%3D 10.1038/nrd1955 16518379
11. Miller JW, Chung C, Kim R, Group FtMS. Randomized, controlled phase III study of ranibizumab (Lucentis) for minimally classic or occult neovascular age-related macular degeneration. American Society of Retina Specialists 23rd Annual Meeting. Montreal, Quebec, Canada; 2005.
12. P.J. Rosenfeld D.M. Brown J.S. Heier, et al. 2006 Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419 1431 1:CAS:528:DC%2BD28XhtVGgtr3M 10.1056/NEJMoa054481 17021318 (Pubitemid 44511557)
13. D.M. Brown P.K. Kaiser M. Michels, et al. 2006 Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 1432 1444 1:CAS:528:DC%2BD28XhtVGgtrrI 10.1056/NEJMoa062655 17021319 (Pubitemid 44511558)
14. Y. Tano M. Ohji EXTEND-I Study Group 2010 EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration Acta Ophthalmol 88 309 316 1:CAS:528:DC%2BC3cXns1eqtr4%3D 10.1111/j.1755-3768.2009.01843.x 20163368
15. R.M. Rich P.J. Rosenfeld C.A. Puliafito, et al. 2006 Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular agerelated macular degeneration Retina 26 495 511 10.1097/01.iae.0000225766.75009.3a 16770255 (Pubitemid 44620390)
16. National Institutes of Health/National Eye Institute. Comparison of age-related macular degeneration treatment trials: CATT Study (Avastin vs Lucentis). 2009; http://clinicaltrials.gov/show/NCT00344227.
17. M. Mitka 2007 Study aims to clarify efficacy, safety and eye drug treatments JAMA 297 1538 1539 1:CAS:528:DC%2BD2sXktFaksrc%3D 10.1001/jama.297.14.1538 17426265 (Pubitemid 46588386)
18. Kiss S. Emerging therapies for the treatment of age-related macular degeneration. The Ophthalmology Report. Jersey City, New Jersey: Direct One Communications, Inc.; 2008;1(2):1-23.
19. C.D. Regillo D.M. Brown P. Abraham, et al. 2008 Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 239 248 1:CAS:528:DC%2BD1cXhtV2hsr4%3D 10.1016/j.ajo.2007.10.004 18222192
20. P.J. Rosenfeld R.M. Rich G.A. Lalwani 2006 Ranibizumab: phase III clinical trial results Ophthalmol Clin North Am 19 361 372 16935211
21. G.A. Lalwani P.J. Rosenfeld A.E. Fung, et al. 2009 A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degenerations: year 2 of the PrONTO study Am J Ophthalmol 148 43 58 1:CAS:528:DC%2BD1MXnsV2ru7g%3D 10.1016/j.ajo.2009.01.024 19376495
22. R.F. Spaide J. Sorenson L. Maranan 2005 Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization Retina 25 685 690 10.1097/00006982-200509000-00001 16141854 (Pubitemid 41254536)
23. W.M. Chan T.Y. Lai Y. Tano D.T. Liu K.K. Li D.S. Lam 2006 Photodynamic therapy in macular diseases of Asian populations: when East meets West Jpn J Ophthalmol 50 161 169 1:CAS:528:DC%2BD28XktFaqsro%3D 10.1007/s10384-005-0259-z 16604394
24. H. She T. Nakazawa A. Matsubara, et al. 2008 Photoreceptor protection after photodynamic therapy using dexamethasone in a rat model of choroidal neovascularization Invest Ophthalmol Vis Sci 49 5008 5014 10.1167/iovs.07-1154 18421085
25. QLT, Inc. Press release: QLT announces positive results from the RADICAL study, 2 June 2009; http://www.qltinc.com/newsCenter/2009/090602.htm.
26. A.J. Augustin S. Puls I. Offermann 2007 Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone Retina 27 133 140 10.1097/IAE.0b013e3180323de7 17290193
27. P.K. Kaiser 2010 Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand? Br J Ophthalmol 94 143 145 10.1136/bjo.2009.159863 20139287
28. QLT, Inc. press release: QLT announces 12-month results from Novartis sponsored Mont Blanc study evaluating standard-fluence Visudyne? combination therapy; http://www.qltinc.com/newsCenter/ 2009/090615.htm.
29. QLT, Inc. press release: 12-month results from Denali study evaluating verteporfin PDT (Visudyne?) combination therapy; http://www.qltinc.com/ newsCenter/2010/100615.htm.
30. A.G. Marneros H. She H. Zambarakji, et al. 2007 Endogenous endostatin inhibits choroidal neovascularization FASEB J 21 3809 3818 1:CAS:528: DC%2BD2sXhsVahtb3M 10.1096/fj.07-8422com 17526870 (Pubitemid 350232338)
31. X. Liu Y. Zhao J. Gao, et al. 2004 Elastic fiber homeostasis requires lysyl oxidase-like 1 protein Nat Genet 36 178 182 1:CAS:528: DC%2BD2cXntlCnsg%3D%3D 10.1038/ng1297 14745449 (Pubitemid 38174378)
32. H.G. Yu X. Liu S. Kiss, et al. 2008 Increased choroidal neovascularization following laser induction in mice lacking lysyl oxidase-like 1 Invest Ophthalmol Vis Sci 49 2599 2605 10.1167/iovs.07-1508 18296663
33. A.O. Edwards R. Ritter 3rd K.J. Abel A. Manning C. Panhuysen L.A. Farrer 2005 Complement factor H polymorphism and age-related macular degeneration Science 308 421 424 1:CAS:528:DC%2BD2MXjtFOntLw%3D 10.1126/science.1110189 15761121 (Pubitemid 40530082)
34. J.L. Haines M.A. Hauser S. Schmidt, et al. 2005 Complement factor H variant increases the risk of age-related macular degeneration Science 308 419 421 1:CAS:528:DC%2BD2MXjtFOntL8%3D 10.1126/science.1110359 15761120 (Pubitemid 40530081)
35. R.J. Klein C. Zeiss E.Y. Chew, et al. 2005 Complement factor H polymorphism in age-related macular degeneration Science 308 385 389 1:CAS:528:DC%2BD2MXjtFOntLs%3D 10.1126/science.1109557 15761122 (Pubitemid 40530070)
36. G.S. Hageman D.H. Anderson L.V. Johnson, et al. 2005 A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration Proc Natl Acad Sci U S A 102 7227 7232 1:CAS:528:DC%2BD2MXks12ns7g%3D 10.1073/pnas.0501536102 15870199 (Pubitemid 40696361)
37. P.J. Francis D.W. Schultz S. Hamon J. Ott R.G. Weleber M.L. Klein 2007 Haplotypes in the complement factor H (CFH) gene: associations with drusen and advanced age-related macular degeneration PLoS ONE 2 e1197 10.1371/journal.pone. 0001197 18043728 (Pubitemid 351673976)
38. K.Y. Lee E.N. Vithana R. Mathur, et al. 2008 Association analysis of CFH, C2, BF, and HTRA1 gene polymorphisms in Chinese patients with polypoidal choroidal vasculopathy Invest Ophthalmol Vis Sci 49 2613 2619 10.1167/iovs.07-0860 18515590
39. I. Kaur S. Katta A. Hussain, et al. 2008 Variants in the 10q26 gene cluster (LOC387715 and HTRA1) exhibit enhanced risk of age-related macular degeneration along with CFH in Indian patients Invest Ophthalmol Vis Sci 49 1771 1776 10.1167/iovs.07-0560 18436811
40. S.H. Sarks D. Van Driel L. Maxwell M. Killingsworth 1980 Softening of drusen and subretinal neovascularization Trans Ophthalmol Soc UK 100 414 422 1:STN:280:DyaL38%2Fmt1yqtA%3D%3D 6171074
41. L.A. Donoso D. Kim A. Frost A. Callahan G. Hageman 2006 The role of inflammation in the pathogenesis of age-related macular degeneration Surv Ophthalmol 51 137 152 10.1016/j.survophthal.2005.12.001 16500214 (Pubitemid 43269939)
42. C. Schwesinger C. Yee R.M. Rohan, et al. 2001 Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium Am J Pathol 158 1161 1172 1:CAS:528:DC%2BD3MXitlOms7o%3D 11238064
43. N.H. Chong J. Keonin P.J. Luthert, et al. 2005 Decreased thickness and integrity of the macular elastic layer of Bruch's membrane correspond to the distribution of lesions associated with age-related macular degeneration Am J Pathol 166 241 251 15632016
44. E.M. Stone T.A. Braun S.R. Russell, et al. 2004 Missense variation in the fibulin 5 gene and age-related macular degeneration N Engl J Med 351 346 353 1:CAS:528:DC%2BD2cXlvFGhurw%3D 10.1056/NEJMoa040833 15269314 (Pubitemid 38944403)
45. G. Thorleifsson K.P. Magnusson P. Sulem, et al. 2007 Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma Science 317 1397 1400 1:CAS:528:DC%2BD2sXpvFWmu7g%3D 10.1126/science.1146554 17690259 (Pubitemid 47417481)
46. B.J. Fan L. Pasquale C.L. Grosskreutz, et al. 2008 DNA sequence variants in the LOXL1 gene are associated with pseudoexfoliation glaucoma in a U.S. clinic-based population with broad ethnic diversity BMC Med Genet 9 5 10.1186/1471-2350-9-5 18254956 (Pubitemid 351454856)
47. C.W. Spraul H.E. Grossniklaus 1997 Characteristics of drusen and Bruch's membrane in postmortem eyes with age-related macular degeneration Arch Ophthalmol 115 267 273 1:STN:280:DyaK2s7pvVaisw%3D%3D 9046265
48. K. Mori A. Ando P. Gehlbach, et al. 2001 Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin Am J Pathol 159 313 320 1:CAS:528:DC%2BD3MXlslamu7s%3D 11438478
49. A.G. Marneros B.R. Olsen 2005 Physiological role of collagen XVIII and endostatin FASEB J 19 716 728 1:CAS:528:DC%2BD2MXktVKrsL4%3D 10.1096/fj.04-2134rev 15857886 (Pubitemid 40617376)
50. D.N. Zacks Q.D. Zheng Y. Han R. Bakhru J.W. Miller 2004 FAS-mediated apoptosis and its relation to intrinsic pathway activation in an experimental model of retinal detachment Invest Ophthalmol Vis Sci 45 4563 4569 10.1167/iovs.04-0598 15557468 (Pubitemid 39564684)
51. T. Nakazawa A. Matsubara K. Noda, et al. 2006 Characterization of cytokine responses for retinal detachment in rats Mol Vis 12 867 878 1:CAS:528:DC%2BD28XovVKntbc%3D 16917487
52. D.N. Zacks V. Hanninen M. Pantcheva E. Ezra C.L. Grosskreutz J.W. Miller 2003 Caspase activation in an experimental model of retinal detachment Invest Ophthalmol Vis Sci 44 1262 1267 10.1167/iovs.02-0492 12601057 (Pubitemid 36297848)
53. T. Nakazawa T. Hisatomi C. Nakazawa, et al. 2007 Monocyte chemoattractant protein 1 mediates retinal detachment-induced photoreceptor apoptosis Proc Natl Acad Sci U S A 104 2425 2430 1:CAS:528:DC%2BD2sXisVShtrc%3D 10.1073/pnas.0608167104 17284607 (Pubitemid 46391413)
54. T. Hisatomi T. Nakazawa K. Noda, et al. 2008 HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice J Clin Invest 118 2025 2038 1:CAS:528:DC%2BD1cXntVCmt78%3D 18497877